Tango Therapeutics, Inc. (NASDAQ: TNGX) has appointed Matthew Gall as its new Chief Financial Officer, effective April 15, 2026. Gall joins the company after resigning from his previous role as CFO of Kalaris Therapeutics on April 14, 2026, and brings a track record of managing capital raises and financial strategy in the biopharma sector, having previously served as CFO at Kalaris and iTeos Therapeutics.
The appointment follows a $225 million capital raise in October 2025 that included an underwritten public offering and a private investment in public equity. The infusion of capital is intended to support Tango’s late‑stage development of vopimetostat, a PRMT5 inhibitor for MTAP‑deleted cancers, and to fund upcoming clinical milestones. Gall’s experience in raising capital and overseeing financial operations is expected to help the company navigate the cash burn associated with advancing vopimetostat toward regulatory submissions and potential partnership opportunities.
CEO Malte Peters said, "Building on our longstanding scientific leadership and recent clinical progress, Tango has a unique opportunity with vopimetostat to bring a potentially paradigm‑shifting treatment to patients with pancreatic and other cancers." Peters also thanked departing CFO Daniella Beckman for her contributions, including taking the company public and leading the recent capital raises. The new CFO will support Tango’s transition from a discovery‑focused organization to a development‑centric model, aligning financial stewardship with the company’s intensified focus on vopimetostat and related assets.
In addition to Gall’s appointment, Tango announced the addition of Yen‑Ching Chua as Chief Development Operations Officer and Janice Kapty as SVP of Corporate Strategy and Project Leadership. These appointments reinforce the company’s commitment to advancing its pipeline and managing the financial and operational demands of late‑stage development.
The CFO change underscores Tango’s strategic emphasis on vopimetostat, which has shown a 27% overall response rate in a Phase 1/2 study of MTAP‑deleted cancers. The company also announced a collaboration with Erasca to evaluate vopimetostat in combination with ERAS‑0015 for specific cancer types, further expanding its development portfolio and potential revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.